蟹足 肿 药膏

蟹足 肿 药膏

蟹足腫係咪非睇醫生不可?自己搽藥膏有無效?

蟹足腫(學名瘢痕疙瘩)的形成,源於幫助傷口癒合的纖維母細胞過度增生,影響外觀之餘,亦有痕癢刺痛的不適感。坊間有不少標榜能去疤、淡疤的藥膏產品,它們的成分是甚麼?可以醫好蟹足腫嗎?

蟹足腫藥膏主要成分為矽膠

市面上的除疤膏通常以矽膠(silicone)為主要成分。矽膠能加強或修補表皮的防水能力,減少疤痕組織的水分流失,紓緩因缺水而引致的炎症反應,從而達至去疤效果。

部分產品添加其他成分,例如維他命C、維他命E或肝素等,這些附加成分對淡化疤痕及紓緩痕癢有一定幫助,但程度因人而異。

及早對症下藥

如欲以坊間產品來預防或治理蟹足腫,必須趁早使用。若蟹足腫已形成一段時間,並處於增生活躍的階段,單靠坊間產品所達到的療效將非常有限。此外,蟹足腫藥膏等產品必須持續使用三個月至一年,方能有顯著效果。

如蟹足腫長於四肢,患者亦可穿戴壓力套來阻止疤痕增生。然而,合適的壓力套一般屬醫療用品,可能要透過職業治療師等相關專業人員提供,普羅大眾未必能輕易購得。

定期觀察疤痕狀態

選用坊間除疤產品未嘗不可,但應密切留意成效,建議定期拍下照片作對比,觀察疤痕的變化。如使用產品一段時間後並無任何改善甚至惡化,便應尋求醫護人員的意見。

分享:

蟹足腫係咪非睇醫生不可?自己搽藥膏有無效?

相關文章

蟹足 肿 药膏

願麗醫美廖苑利醫師分享診間故事;許多男性患者會問我:「醫師,我胸口沒有受傷,怎麼會有蟹足腫?」那我會反問:「你的痘痘是不是長在胸口?」常常得到的答案是肯定的。痘痘如果摳破了,也是一個傷口!所以身上的蟹足腫,常常是長完痘痘的後遺症,有些人甚至在下巴長完痘痘之後,也會留下蟹足腫的疤痕。

蟹足 肿 药膏

至於為什麼會有蟹足腫呢?其實,這是一種不正常增生的疤痕組織,常見於身體肌肉張力較強的部位,如胸口、上手臂、背部等。當皮膚受創傷、或是痘痘被摳破而傷到真皮時,有蟹足腫體質的人在傷疤癒合的時候,身體組織會得到不斷產生疤痕的訊息,所以當傷口疤痕長過頭了,就在外觀上形成了肥厚性突起的組織,並伴隨紅腫、發癢等症狀。

蟹足腫疤痕出現時,該怎麼辦呢?

目前針對蟹足腫的治療方式,常見的有:

1.注射治療

在蟹足腫疤痕的皮下,注射類固醇成分針劑,這是目前最簡單、效果最顯著的蟹足腫治療方式。在接受類固醇針劑注射之後,肥厚的蟹足腫疤痕會漸漸軟化、變平坦,但對於疤痕組織的顏色,並無法淡化消失。

注射治療每隔2-4周注射一次,通常要經過數次的注射才能讓疤痕平復,實際注射次數要看疤痕的大小、硬度、厚度與反應效果而定。常常有人問我:「廖醫師!打類固醇耶!這不是很可怕嗎?會不會有副作用啊?」其實,不用這麼擔心,因為皮下局部注射,大部份的藥劑會集中在皮下發揮作用,人體吸收藥量很有限;再來,我們將注射間隔時間拉長,並不是每天施打,並不會對人體產生副作用的。

2.冷凍治療

除了注射治療之外,冷凍治療也常用來治療蟹足腫。冷凍治療是以低溫的液態氮針對蟹足腫的部位加以噴拭,主要原理是靠瞬間的低溫讓纖維母細胞安靜、不活躍,逐漸使肥厚的疤痕平復,但缺點在於剛作完時,患部容易產生水泡、結痂,如果出現水泡時,約需1-2週時間方能痊癒。

3.外用藥膏

外用擦拭藥膏也可以治療蟹足腫的問題,使用的藥膏可以分成兩類,第一類是含有抗血栓性成分的藥膏,如heparin藥膏,可以讓蟹足腫慢慢平復,但所需時間比注射治療要來得長;另一類是貼矽膠貼片或擦矽膠藥膏,在臨床研究上都證實改善蟹足腫。

4.雷射治療

包括脈衝光、染料雷射治療,不管用哪一種方法,都是利用局部微血管循環萎縮的原理,讓纖維母細胞得不到養份供給,來抑制疤痕增生。

廖苑利醫師認為,目前治療蟹足腫的方式,以類固醇注射搭配藥膏或矽膠貼片為佳!蟹足腫疤痕平坦之後,仍然會有暗紅色的色疤,這個部份,如果還在意的話,可以打脈衝光來淡化色澤。

廖醫師強調,有些患者會發現,以前治療過,一陣子沒打針結果又長出來了。其實,這和局部組織的張力有很大的關係,一般說來,長在胸口部分的蟹足腫,是比較容易復發的,在接受注射治療已恢復平坦的狀況下,建議患者還是要長期擦藥膏來維持效果!其他部位的蟹足腫,治療過後會再復發的機率是較低的!

CN1181268A - 一种消除疤痕的药膏 - Google Patents

一种消除疤痕的药膏 Download PDF

Info

Publication numberCN1181268A CN1181268A CN 97118390 CN97118390A CN1181268A CN 1181268 A CN1181268 A CN 1181268A CN 97118390 CN97118390 CN 97118390 CN 97118390 A CN97118390 A CN 97118390A CN 1181268 A CN1181268 A CN 1181268AAuthorityCNChinaPrior art keywordsoleum sesamiointmentcalomelasaranearealgarPrior art date1997-10-28Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) PendingApplication numberCN 97118390Other languages English (en) Inventor黄钦Original Assignee黄钦Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)1997-10-28Filing date1997-10-28Publication date1998-05-13 1997-10-28 Application filed by 黄钦 filed Critical 黄钦 1997-10-28 Priority to CN 97118390 priority Critical patent/CN1181268A/zh 1998-05-13 Publication of CN1181268A publication Critical patent/CN1181268A/zh Status Pending legal-status Critical Current

Links

  • Espacenet
  • Global Dossier
  • Discuss
  • 231100000241 scar Toxicity 0.000 title abstract description 7
  • 239000002674 ointment Substances 0.000 claims abstract description 15
  • 241001161070 Calomela Species 0.000 claims abstract description 10
  • 238000003756 stirring Methods 0.000 claims abstract description 4
  • 239000003814 drug Substances 0.000 claims description 19
  • QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound data:image/svg+xml;base64,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 data:image/svg+xml;base64,PD94bWwgdmVyc2lvbj0nMS4wJyBlbmNvZGluZz0naXNvLTg4NTktMSc/Pgo8c3ZnIHZlcnNpb249JzEuMScgYmFzZVByb2ZpbGU9J2Z1bGwnCiAgICAgICAgICAgICAgeG1sbnM9J2h0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnJwogICAgICAgICAgICAgICAgICAgICAgeG1sbnM6cmRraXQ9J2h0dHA6Ly93d3cucmRraXQub3JnL3htbCcKICAgICAgICAgICAgICAgICAgICAgIHhtbG5zOnhsaW5rPSdodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rJwogICAgICAgICAgICAgICAgICB4bWw6c3BhY2U9J3ByZXNlcnZlJwp3aWR0aD0nODVweCcgaGVpZ2h0PSc4NXB4JyB2aWV3Qm94PScwIDAgODUgODUnPgo8IS0tIEVORCBPRiBIRUFERVIgLS0+CjxyZWN0IHN0eWxlPSdvcGFjaXR5OjEuMDtmaWxsOiNGRkZGRkY7c3Ryb2tlOm5vbmUnIHdpZHRoPSc4NS4wJyBoZWlnaHQ9Jzg1LjAnIHg9JzAuMCcgeT0nMC4wJz4gPC9yZWN0Pgo8cGF0aCBjbGFzcz0nYm9uZC0wIGF0b20tMCBhdG9tLTEnIGQ9J00gMTkuNiw1My43IEwgMjguNiw0OC41JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0wIGF0b20tMCBhdG9tLTEnIGQ9J00gMjguNiw0OC41IEwgMzcuNiw0My4zJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRkNDNjMzO3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xIGF0b20tMSBhdG9tLTInIGQ9J00gNDYuNSwzOC4yIEwgNTUuNSwzMy4wJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRkNDNjMzO3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xIGF0b20tMSBhdG9tLTInIGQ9J00gNTUuNSwzMy4wIEwgNjQuNSwyNy43JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0yIGF0b20tMSBhdG9tLTMnIGQ9J00gNDMuMyw0OS4zIEwgNDcuOCw1Ny4xJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRkNDNjMzO3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0yIGF0b20tMSBhdG9tLTMnIGQ9J00gNDcuOCw1Ny4xIEwgNTIuMyw2NC45JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0yIGF0b20tMSBhdG9tLTMnIGQ9J00gNDguNyw0Ni4yIEwgNTMuMiw1NC4wJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRkNDNjMzO3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0yIGF0b20tMSBhdG9tLTMnIGQ9J00gNTMuMiw1NC4wIEwgNTcuNyw2MS44JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0zIGF0b20tMSBhdG9tLTQnIGQ9J00gNDIuMCwzNC43IEwgMzcuNiwyNi45JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRkNDNjMzO3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0zIGF0b20tMSBhdG9tLTQnIGQ9J00gMzcuNiwyNi45IEwgMzMuMSwxOS4yJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0zIGF0b20tMSBhdG9tLTQnIGQ9J00gMzYuNywzNy44IEwgMzIuMiwzMC4wJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRkNDNjMzO3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0zIGF0b20tMSBhdG9tLTQnIGQ9J00gMzIuMiwzMC4wIEwgMjcuNywyMi4zJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoxLjBweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8dGV4dCB4PSczLjQnIHk9JzYyLjUnIGNsYXNzPSdhdG9tLTAnIHN0eWxlPSdmb250LXNpemU6MTJweDtmb250LXN0eWxlOm5vcm1hbDtmb250LXdlaWdodDpub3JtYWw7ZmlsbC1vcGFjaXR5OjE7c3Ryb2tlOm5vbmU7Zm9udC1mYW1pbHk6c2Fucy1zZXJpZjt0ZXh0LWFuY2hvcjpzdGFydDtmaWxsOiNFODQyMzUnID5IPC90ZXh0Pgo8dGV4dCB4PScxMS4zJyB5PSc2Mi41JyBjbGFzcz0nYXRvbS0wJyBzdHlsZT0nZm9udC1zaXplOjEycHg7Zm9udC1zdHlsZTpub3JtYWw7Zm9udC13ZWlnaHQ6bm9ybWFsO2ZpbGwtb3BhY2l0eToxO3N0cm9rZTpub25lO2ZvbnQtZmFtaWx5OnNhbnMtc2VyaWY7dGV4dC1hbmNob3I6c3RhcnQ7ZmlsbDojRTg0MjM1JyA+TzwvdGV4dD4KPHRleHQgeD0nMzguMicgeT0nNDcuMCcgY2xhc3M9J2F0b20tMScgc3R5bGU9J2ZvbnQtc2l6ZToxMnB4O2ZvbnQtc3R5bGU6bm9ybWFsO2ZvbnQtd2VpZ2h0Om5vcm1hbDtmaWxsLW9wYWNpdHk6MTtzdHJva2U6bm9uZTtmb250LWZhbWlseTpzYW5zLXNlcmlmO3RleHQtYW5jaG9yOnN0YXJ0O2ZpbGw6I0ZDQzYzMycgPlM8L3RleHQ+Cjx0ZXh0IHg9JzY1LjEnIHk9JzMxLjQnIGNsYXNzPSdhdG9tLTInIHN0eWxlPSdmb250LXNpemU6MTJweDtmb250LXN0eWxlOm5vcm1hbDtmb250LXdlaWdodDpub3JtYWw7ZmlsbC1vcGFjaXR5OjE7c3Ryb2tlOm5vbmU7Zm9udC1mYW1pbHk6c2Fucy1zZXJpZjt0ZXh0LWFuY2hvcjpzdGFydDtmaWxsOiNFODQyMzUnID5PPC90ZXh0Pgo8dGV4dCB4PSc3My43JyB5PSczMS40JyBjbGFzcz0nYXRvbS0yJyBzdHlsZT0nZm9udC1zaXplOjEycHg7Zm9udC1zdHlsZTpub3JtYWw7Zm9udC13ZWlnaHQ6bm9ybWFsO2ZpbGwtb3BhY2l0eToxO3N0cm9rZTpub25lO2ZvbnQtZmFtaWx5OnNhbnMtc2VyaWY7dGV4dC1hbmNob3I6c3RhcnQ7ZmlsbDojRTg0MjM1JyA+SDwvdGV4dD4KPHRleHQgeD0nNTMuOCcgeT0nNzMuOScgY2xhc3M9J2F0b20tMycgc3R5bGU9J2ZvbnQtc2l6ZToxMnB4O2ZvbnQtc3R5bGU6bm9ybWFsO2ZvbnQtd2VpZ2h0Om5vcm1hbDtmaWxsLW9wYWNpdHk6MTtzdHJva2U6bm9uZTtmb250LWZhbWlseTpzYW5zLXNlcmlmO3RleHQtYW5jaG9yOnN0YXJ0O2ZpbGw6I0U4NDIzNScgPk88L3RleHQ+Cjx0ZXh0IHg9JzIyLjcnIHk9JzIwLjEnIGNsYXNzPSdhdG9tLTQnIHN0eWxlPSdmb250LXNpemU6MTJweDtmb250LXN0eWxlOm5vcm1hbDtmb250LXdlaWdodDpub3JtYWw7ZmlsbC1vcGFjaXR5OjE7c3Ryb2tlOm5vbmU7Zm9udC1mYW1pbHk6c2Fucy1zZXJpZjt0ZXh0LWFuY2hvcjpzdGFydDtmaWxsOiNFODQyMzUnID5PPC90ZXh0Pgo8L3N2Zz4K OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 16
  • 210000000589 Cicatrix Anatomy 0.000 claims description 12
  • 241000131808 Scolopendra Species 0.000 claims description 10
  • 239000002689 soil Substances 0.000 claims description 10
  • 239000007766 cera flava Substances 0.000 claims description 9
  • 229910052957 realgar Inorganic materials 0.000 claims description 9
  • 241000256844 Apis mellifera Species 0.000 claims description 6
  • 238000002360 preparation method Methods 0.000 claims description 4
  • 239000002994 raw material Substances 0.000 claims description 4
  • 206010024453 Ligament sprain Diseases 0.000 claims description 2
  • 239000003795 chemical substances by application Substances 0.000 claims description 2
  • 230000000694 effects Effects 0.000 abstract description 6
  • 241000239290 Araneae Species 0.000 abstract 1
  • 241000131329 Carabidae Species 0.000 abstract 1
  • 241000258920 Chilopoda Species 0.000 abstract 1
  • 241000264877 Hippospongia communis Species 0.000 abstract 1
  • 210000003660 Reticulum Anatomy 0.000 abstract 1
  • 238000010438 heat treatment Methods 0.000 abstract 1
  • 239000000463 material Substances 0.000 abstract 1
  • 210000003491 Skin Anatomy 0.000 description 6
  • 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
  • 210000004369 Blood Anatomy 0.000 description 3
  • 206010053615 Thermal burn Diseases 0.000 description 3
  • 230000001139 anti-pruritic Effects 0.000 description 3
  • 239000003908 antipruritic agent Substances 0.000 description 3
  • 239000008280 blood Substances 0.000 description 3
  • 201000010099 disease Diseases 0.000 description 3
  • 230000002980 postoperative Effects 0.000 description 3
  • 238000011084 recovery Methods 0.000 description 3
  • 206010000496 Acne Diseases 0.000 description 2
  • 210000001117 Keloid Anatomy 0.000 description 2
  • 208000002260 Keloid Diseases 0.000 description 2
  • 206010023330 Keloid scar Diseases 0.000 description 2
  • 208000002193 Pain Diseases 0.000 description 2
  • 230000003110 anti-inflammatory Effects 0.000 description 2
  • 238000004519 manufacturing process Methods 0.000 description 2
  • 230000037311 normal skin Effects 0.000 description 2
  • 239000000047 product Substances 0.000 description 2
  • 230000001225 therapeutic Effects 0.000 description 2
  • 241000349731 Afzelia bipindensis Species 0.000 description 1
  • 210000000481 Breast Anatomy 0.000 description 1
  • 210000001736 Capillaries Anatomy 0.000 description 1
  • 208000001387 Causalgia Diseases 0.000 description 1
  • 229940121657 Clinical Drug Drugs 0.000 description 1
  • 241000555268 Dendroides Species 0.000 description 1
  • 241000196324 Embryophyta Species 0.000 description 1
  • 206010020718 Hyperplasia Diseases 0.000 description 1
  • 206010020880 Hypertrophy Diseases 0.000 description 1
  • 241000282346 Meles meles Species 0.000 description 1
  • 210000004080 Milk Anatomy 0.000 description 1
  • 231100000614 Poison Toxicity 0.000 description 1
  • 208000003251 Pruritus Diseases 0.000 description 1
  • 206010027699 Skin injury Diseases 0.000 description 1
  • 206010040943 Skin ulcer Diseases 0.000 description 1
  • 206010072170 Skin wound Diseases 0.000 description 1
  • 230000003187 abdominal Effects 0.000 description 1
  • 230000000202 analgesic Effects 0.000 description 1
  • 230000017531 blood circulation Effects 0.000 description 1
  • 201000009541 complex regional pain syndrome Diseases 0.000 description 1
  • 239000006071 cream Substances 0.000 description 1
  • 229940079593 drugs Drugs 0.000 description 1
  • 238000003379 elimination reaction Methods 0.000 description 1
  • 239000004744 fabric Substances 0.000 description 1
  • 239000012467 final product Substances 0.000 description 1
  • 241000411851 herbal medicine Species 0.000 description 1
  • 235000008216 herbs Nutrition 0.000 description 1
  • 230000002401 inhibitory effect Effects 0.000 description 1
  • 239000008267 milk Substances 0.000 description 1
  • 235000013336 milk Nutrition 0.000 description 1
  • 238000005457 optimization Methods 0.000 description 1
  • 230000000144 pharmacologic effect Effects 0.000 description 1
  • 239000002574 poison Substances 0.000 description 1
  • 230000001737 promoting Effects 0.000 description 1
  • 231100000486 side effect Toxicity 0.000 description 1
  • 231100000019 skin ulcer Toxicity 0.000 description 1
  • 210000001519 tissues Anatomy 0.000 description 1
  • 230000029663 wound healing Effects 0.000 description 1

Abstract

本发明公开了一种消除疤痕的药膏,它是以蜂房、蜈蚣、蜘蛛、土蹩虫、轻粉、冰片、雄黄、紫草、香油、蜂蜡中药为原料,经加工预处理后,按比例配制,再经高温粘制、搅拌,即为药膏,具有配方独特、疗效显著、无副作用、药源广泛,适于各种术后及烧、烫伤疤痕的外用敷抹。

Description

一种消除疤痕的药膏

本发明涉及一种治疗疤痕的药物,具体说是以中草药为原料制备的中成药,本发明还涉及该药物的制备方法。

疤痕疙瘩,也称蟹足肿。是一种皮肤组织的良性增生,为皮肤破损后高起的肿块,既形成坚硬面具有弹性的结节或斑块,表面光滑、无毛、边界清楚,周围可见扩张的毛细血管呈树枝状增生,常觉瘙痒、灼痛或刺痛。原因多为手术后、烫伤,烧伤后或疮病愈合后,余毒未尽,气血不通凝聚而成。

目前,医学所拥有的治疗疤痕药物,多用在当皮肤受伤的当时起到消炎、止痛的作用,而对于作各种手术时就不能立即用药了。因为术后的伤口需缝合、消炎、保护伤口愈合,拆线后,皮肤组织的良性增生已经形成,出现疤良或疙瘩,这时用药最大的效果也仅对止痒或控制其增长速度,很难彻底消除疤痕肿块。

在我国民间,医治烧伤,烫伤等采用獾油作为良药,但獾的数量有限,也没有得到普遍推广,另一方面,对于加工、存放有许多不便之处。所以目前尚没有一种既有良好疗效,又安全可靠的药物。

本发明的目的在于提供一种具有止痒、止痛、抑制皮肤组织的疤痕继续良性增生、蔓延,改善和消除疤痕肿块的药膏。

本发明的另一目的是提供该药膏膏剂的制备方法。

本发明的解决方案是基于祖国医学对伤口疤痕增生的机理的认识及治疗原则,参考现代药理研究成就,从祖国医药宝库中,筛选出止痒、止痛、消除皮肤疤良良性增生、天然植物草药,按中医理论组方,提取精华,改善皮肤伤口组织,使其恢复正常皮肤,不留疤痕的作用。

本发明药物是由下列组份制成的(用量为重量份):蜂房10-20份  蜈蚣2-10份   蜘蛛2-10份  土蹩虫5-18份轻粉3-16份   冰片2-6份    雄黄3-15份  紫草3-16份香油40-50份  蜂蜡20-28份本发明药物的配方优选重量配比范围:蜂房8-18份    蜈蚣1.5-8份 蜘蛛1.5-8份  土蹩虫4-16份轻粉2-10份    冰片1-4份   雄黄2-12份   紫  草2-13份香油38-45份   蜂蜡18-25份本发明药物的最佳重量配比是:蜂房12-15份  蜈蚣3-8份   蜘蛛3-8份   土蹩虫6-15份轻粉2-8份    冰片2-5份   雄黄3-10份  紫草4-12份香油41-48份  蜂蜡21-27份将上述各组份制成本发明药物的生产方法:1、先职蜂房烘干备用。

2、将香油加热到一定温度,职蜂房、蜈蚣、蜘蛛、土蹩虫、紫草放入,待炸至焦状,弃去残渣。

3、再职轻粉、冰片、雄黄加入香油内均匀搅拌,待香油温度降至40°-50°时,最后加入蜂蜡即为成品。

本发明药物临床使用效果有下述优点:1、疤痕消除药膏为外用药,对烧、烫伤,尤其是对各部位的术后留下的疤痕治疗效果明显,一般用药1-2次后肿块可基本消除,可恢复或接近正常皮肤,最后彻底痊愈。

2、具有对疤痕肿块起到消热解毒、活血化瘀之功效,使用安全、方便,可根据肿块面积大小,将药膏涂抹在纸、布上,直接敷设于肿块部位即可。

3、本发明的药膏对皮肤无任何副作用,不受季节使用限制。如春、秋、冬季用药效果更佳,不需住院治疗,治愈快捷、简便。

为表明本发明药膏对各种疤痕的治疗效果,本发明经对58例系统临床观察,并选择胸、腹部手术后的疤痕32例,治疗时间为40-80天痊愈,总有效率占97%,无效占3%;治疗局部烧伤留下的疤痕12例,治疗时间为45-65天痊愈,总有效率占83%,无效占17%;治疗局部烫伤留下疤痕14侧,治疗时间为35-60天痊愈,总有效率占91.3%,无效占8.7%。

实施例:按下述配比称职原料:蜂房30克  蜈蚣5克    蜘蛛5克    土蹩虫15克   轻粉9克冰片3克   雄黄9克    紫草10克   香  油500克  蜂蜡200克制备方法如下:先职蜂房烘干备用,然后将香油加垫至200℃以上,职蜂房、蜈蚣、蜘蛛、土蹩虫、紫草放入高温油内炸至焦状,并弃去残渣,再职轻粉、冰片、雄黄加入香油内均匀搅拌,待香油温度降至40°-50°时,加入蜂蜡成膏剂,即为成品。

Claims (5)

1.一种消除疤痕的药膏,其特征在于它是由下述重量配比的原料制成的药剂:蜂  房10-20份    蜈蚣2-10份    蜘蛛2-10份    土蹩虫5-18份轻粉3-16份  冰片2-6份  雄黄3-15份  紫草3-16份香油40-50份  蜂蜡20-28份

2.按权利要求1所述的药膏,其中各原料的重量配比是:蜂房12-15份  蜈蚣3-8份    蜘蛛3-8份    土蹩虫6-15份轻粉2-8份    冰片2-5份    雄黄3-10份   紫  草4-12份香油41-48份  蜂蜡21-27份

3.按权利要求1所述的药膏,其中各原料的重量配比是:蜂房8-18份    蜈蚣1.5-8份    蜘蛛1.5-8份    土蹩虫4-16份轻粉2-10份    冰片1-4份      雄黄2-12份     紫草2-13份香油38-45份   蜂蜡18-25份

4.按权利要求1、2或3所述的药膏,其特征在于所述的药剂为药剂学上所说的膏剂。

5.一种用于上述药膏的制备方法,职蜂房烘干备用,再将香油加热至200℃以上,职蜂房、蜈蚣、蜘蛛、土蹩虫、紫草放入油内炸至焦状,弃残渣、然后职轻粉、冰片、雄黄加入香油内均匀搅拌,于香油温度降至40°-50°时,加入蜂蜡即成膏剂成品。

CN 97118390 1997-10-28 1997-10-28 一种消除疤痕的药膏 Pending CN1181268A (zh)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN 97118390 CN1181268A (zh) 1997-10-28 1997-10-28 一种消除疤痕的药膏

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN 97118390 CN1181268A (zh) 1997-10-28 1997-10-28 一种消除疤痕的药膏

Publications (1)

Publication NumberPublication Date
CN1181268A true CN1181268A (zh) 1998-05-13

Family

ID=5174794

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN 97118390 Pending CN1181268A (zh) 1997-10-28 1997-10-28 一种消除疤痕的药膏

Country Status (1)

CountryLink
CN (1) CN1181268A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1101688C (zh) * 2000-07-10 2003-02-19 刘发良 治疗疤痕疙瘩的中草药制剂
CN107582598A (zh) * 2017-08-21 2018-01-16 安徽陛颜祛斑技术研究有限公司 一种祛除疤痕霜及其制备工艺
  • 1997
    • 1997-10-28 CN CN 97118390 patent/CN1181268A/zh active Pending

Cited By (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1101688C (zh) * 2000-07-10 2003-02-19 刘发良 治疗疤痕疙瘩的中草药制剂
CN107582598A (zh) * 2017-08-21 2018-01-16 安徽陛颜祛斑技术研究有限公司 一种祛除疤痕霜及其制备工艺

Similar Documents

PublicationPublication DateTitle
CN102198159B (zh) 2012-07-04 一种治疗烧伤疮疡的药物及采用该药物制成的创面贴
CN101912532B (zh) 2012-01-04 一种治疗烧伤、烫伤及冻伤的外用中药制剂
CN101569696A (zh) 2009-11-04 用于创伤性伤口的中药
CN108186711A (zh) 2018-06-22 促进伤口愈合的药物组合物
CN102526662A (zh) 2012-07-04 用于人体穴位敷贴的治疗哮喘的中药磁疗外贴膏
CN103690903B (zh) 2016-04-13 一种治疗烧烫伤褥疮等外伤疾病的复方中药制剂
CN103230470B (zh) 2015-09-09 一种治疗烧烫伤的外用中药制剂及其制备方法
CN1181268A (zh) 1998-05-13 一种消除疤痕的药膏
CN1137711C (zh) 2004-02-11 一种治疗烧烫伤创疡的乳膏及其制备方法
CN1939313A (zh) 2007-04-04 一种用于治疗外伤的外用制剂
CN1261128C (zh) 2006-06-28 治疗烧烫伤的药物及其制备方法
CN1217683C (zh) 2005-09-07 一种痔瘘洗液及其制备方法
CN1457860A (zh) 2003-11-26 一种治疗痔疮的中药
CN1068495A (zh) 1993-02-03 生肌护肤烧伤膏及其制备方法
CN107050302A (zh) 2017-08-18 治疗烧烫伤的外用中药
CN101292999B (zh) 2011-04-20 一种治疗外伤的膏药
CN102133324B (zh) 2012-04-18 一种治疗表皮烧烫伤的药膏
CN105288456A (zh) 2016-02-03 一种治疗烫烧伤药物的制备方法
CN109331106A (zh) 2019-02-15 用于创面修复的红药制剂及其制备方法
CN103494882A (zh) 2014-01-08 促进伤口愈合的中药制剂及其制备方法
CN1478514A (zh) 2004-03-03 一种治疗创伤的中药
CN1191078C (zh) 2005-03-02 一种治疗烧烫伤的外用膏剂
CN1168454C (zh) 2004-09-29 巨胜油及其制法
CN103230471A (zh) 2013-08-07 一种治疗烧烫伤的外用药物及其制备方法
CN102475817A (zh) 2012-05-30 祛腐生肌散及制备方法
DateCodeTitleDescription
1998-05-13 C06 Publication
1998-05-13 PB01 Publication
2001-02-28 C01 Deemed withdrawal of patent application (patent law 1993)
2001-02-28 WD01 Invention patent application deemed withdrawn after publication